Amphastar Pharmaceuticals (AMPH) Total Debt (2013 - 2026)

Amphastar Pharmaceuticals' Total Debt history runs 14 years deep, the most recent figure standing at $611.5 million for Q1 2026.

• On a quarterly basis, Total Debt rose 1.22% year-over-year to $611.5 million in Q1 2026; TTM through Mar 2026 was $611.5 million, a 1.22% increase from a year earlier, with the FY2025 full-year figure at $610.4 million, up 1.42% from the prior year.
• Total Debt held at $611.5 million in Q1 2026 per AMPH's latest filing, from $610.4 million in the prior quarter.
• Across five years, Total Debt topped out at $638.6 million in Q3 2023 and bottomed at $75.0 million in Q1 2023.
• The 5-year median for Total Debt is $594.4 million (2024), against an average of $443.1 million.
• Across the five-year window, Total Debt surged 743.74% in 2023 and slipped 6.57% in 2024, its largest moves.
• Year by year, Total Debt stood at $75.9 million in 2022, then jumped by 677.51% to $590.0 million in 2023, then rose by 2.01% to $601.9 million in 2024, then advanced by 1.42% to $610.4 million in 2025, then advanced by 0.18% to $611.5 million in 2026.
• Per Business Quant, the three latest AMPH Total Debt figures stand at $611.5 million (Q1 2026), $610.4 million (Q4 2025), and $609.5 million (Q3 2025).